No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PTVE Pactiv Evergreen
- 14.520
- +0.380+2.69%
Close Apr 19 16:00 ET
- 14.520
- 0.0000.00%
Post 16:17 ET
2.60BMarket Cap-11523P/E (TTM)
14.530High14.070Low443.24KVolume14.070Open14.140Pre Close6.39MTurnover1.11%Turnover RatioLossP/E (Static)179.15MShares15.51052wk High1.93P/B582.38MFloat Cap6.57152wk Low0.40Dividend TTM40.11MShs Float17.393Historical High2.75%Div YieldTTM3.25%Amplitude6.571Historical Low14.425Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Is There Now An Opportunity In Pactiv Evergreen Inc. (NASDAQ:PTVE)?
Pactiv Evergreen Inc. (PTVE) Registers a Bigger Fall Than the Market: Important Facts to Note
Pactiv Evergreen Inc. Schedules First Quarter 2024 Financial Results
LAKE FOREST, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Pactiv Evergreen (NASDAQ:PTVE) today announced the following details for its first quarter 2024 earnings release and teleconference call. Earnings
Is Pactiv Evergreen (PTVE) Stock Outpacing Its Consumer Discretionary Peers This Year?
Should You Think About Buying Pactiv Evergreen Inc. (NASDAQ:PTVE) Now?
While Pactiv Evergreen Inc. (NASDAQ:PTVE) might not have the largest market cap around , it saw a double-digit share price rise of over 10% in the past couple of months on the NASDAQGS. The rece
Pactiv Evergreen Inc. (PTVE) Stock Moves -1.1%: What You Should Know
Comments
Despite the current undervaluation of PTVE, the negative growth outlook introduces a level of uncertainty and risk. Potential investors are advised to research further into the stock and consider the risks associated with negative future growth prospects.
Is Now The Time To Look At Buying Pactiv Evergreen Inc. (NASDAQ:PTVE)?The pessimism of the analyst cohort reflected in Pactiv Evergreen's declining revenue forecasts might impact its stocks. The current high P/S may not be sustainable due to these decreasing revenues.
Although Pactiv Evergreen's dividends were covered by free cash flow, its lack of profitability last year is worrisome. Dividend investors need to see evidence of sustained profitability to be positive.
ColumnsToday's pre-market stock movers: CRM, WB, LI, NIO and more
Gainers:
• $Victoria's Secret(VSCO.US$ +10.4% (In reaction to earnings)
• $Salesforce(CRM.US$ +9.0% (In reaction to earnings)
• $Navigator(NVGS.US$ +4.9% (names Mads Peter Zacho as CEO)
• $Weibo(WB.US$ +4.7% (In reaction to earnings)
• $CAE Inc(CAE.US$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics(AXSM.US$ +3.1% (Late-Breaking Presentations of P...
• $Victoria's Secret(VSCO.US$ +10.4% (In reaction to earnings)
• $Salesforce(CRM.US$ +9.0% (In reaction to earnings)
• $Navigator(NVGS.US$ +4.9% (names Mads Peter Zacho as CEO)
• $Weibo(WB.US$ +4.7% (In reaction to earnings)
• $CAE Inc(CAE.US$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics(AXSM.US$ +3.1% (Late-Breaking Presentations of P...
21
ColumnsToday's pre-market stock movers: BNTX, JPM, RIVN, HPQ and more
Gainers:
• $Genco Shipping & Trading(GNK.US$ +4.7% (positive Barrons article)
• $NextDecade(NEXT.US$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways(CMPS.US$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo(GOEV.US$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg(AXL.US$ +3.7% (pr...
• $Genco Shipping & Trading(GNK.US$ +4.7% (positive Barrons article)
• $NextDecade(NEXT.US$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $COMPASS Pathways(CMPS.US$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $Canoo(GOEV.US$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $American Axle & Mfg(AXL.US$ +3.7% (pr...
21
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg